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Lesson
This report illustrates the difficulties in diagnosing complex
cases and demonstrates how whole exome sequencing can
resolve complex phenotypes.
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Introduction
Myoclonic epilepsy and developmental regression are
notoriously heterogeneous disorders, with a multi-
tude of possible aetiologies. Whole exome sequencing
is proving capable of facilitating the discovery of
novel causal mutations for rare Mendelian
disease of unknown aetiology.1,2 We discuss the
application of whole exome sequencing in a case of
severe myoclonic epilepsy and Fanconi syndrome and
elucidate the features of a complex phenotype.
Patient presentation
An eight-year-old Pakistani boy (Figure 1) with history
of myoclonic status epilepticus, myopathy, hypotonia,
weakness and severe physical disability presented to
nephrology following four weeks of pyrexia of unknown
origin refractory to multiple antibiotics, deranged
inﬂammatory markers and electrolyte disturbances.
Born at term with normal development during
infancy, he took his ﬁrst independent steps at 12
months but was unsteady with frequent falls. At 13
months, he developed head shaking, eyelid ﬂickering
and tremors of the hands and legs. At 22 months, he
developed atonic drop attacks preceded by myoclonic
jerks of his right arm. An electro-encephalogram
showed very high-amplitude slow wave activity and
he received oral prednisolone with seizure resolution
and improvement in his gait. Steroid therapy was
weaned, and sodium valproate was introduced.
Aged three, two episodes of non-convulsive status
epilepticus preceded rapid developmental regression
leaving our patient non-ambulant, hypotonic, apha-
sic and aphagic and requiring gastrostomy feeds. He
had a marked myopathic facies and choreiform
movements of the right arm. Medications trialled
included ethosuximide, clobazam, acetazolamide,
levetiracetam, topiramate, zonisamide, stiripentol
and pulsed steroids without any enduring beneﬁt.
His parents reported consanguinity but did not dis-
close their degree of relatedness. His maternal uncle
died from Leigh syndrome aged eight.
On admission, he was systemically unwell and feb-
rile with no focus of infection. He had raised inﬂam-
matory markers; hypokalaemia; hypophosphataemia;
heavy proteinuria primarily of tubular origin, with a
markedly elevated urinary b2-microglobulin and only
modestly elevated urine albumin/creatinine ratio;
normal anion gap metabolic acidosis; leucocytosis;
and a normocytic anaemia. He was diagnosed with
Fanconi syndrome and received electrolyte replace-
ment therapy.
Investigations
A repeat electroencephalogram was highly abnormal
with continuous spike activity maximum in the left
centrotemporal and central areas. Magnetic reso-
nance imaging of the brain showed generalised cere-
bral and cerebellar atrophy. Cerebrospinal ﬂuid
! 2016 The Author(s)
Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.
creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided
the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).
Journal of the Royal Society of Medicine Open;
0(0) 1–4
DOI: 10.1177/2054270415623145
 at Southampton General Hosp tal on June 6, 2016shr.sagepub.comDownloaded from 
studies were normal. A muscle biopsy did not show
any morphological or enzyme-based evidence of
mitochondrial myopathy. Activity of electron trans-
port chain complexes I-V was within normal limits.
Testing for mitochondrial DNA depletion showed an
intermediate result of 44% of mean normal levels.
Whole gene sequencing revealed no mutations in
POLG, and mitochondrial DNA analysis was nega-
tive for mutations m3243A>G and m8344A>G.
This patient was a candidate for whole exome sequen-
cing and genomic DNA was extracted and analysed.
Data analysis
In total, 24,543 variants were called. Low-percentage
heterozygosity in the proband indicated parental con-
sanguinity. Initial analysis was targeted towards
nuclear-encoded mitochondrial genes with no rare
recessive mutations found, but pan-exomic interroga-
tion identiﬁed a rare homozygous missense variant
in KCTD7 (c.332C>A; pLeu108Met), previously
described in Pakistani siblings from consanguineous
parents with a near-identical phenotype (Table 1).3
The mutation was conﬁrmed heterozygous in the pro-
band’s parents.
Discussion
The potassium channel tetramerization domain con-
taining 7 (KCTD7) gene is highly expressed in the
brain.3 Recessive mutations in KCTD7 have been
associated with progressive myoclonic epilepsy type
3 (PME), a severe neurodegenerative disease charac-
terised by myoclonic seizures and developmental
regression.3–5 Although the Leu108Met mutation
explains many features of our patient’s phenotype,
it does not explain his Fanconi syndrome nor pyrexia
of unknown origin. Fanconi syndrome was therefore
attributed to valproate therapy.
Valproate-induced Fanconi syndrome (VIF)
Fanconi syndrome is a very rare complication of val-
proate therapy, yet reported cases are almost exclu-
sively observed in severely disabled individuals,
particularly those who are tube fed.6,7 There is fre-
quently a prolonged lag period (up to 13 years)6
between drug initiation and onset of symptoms,
which may deter clinicians from a valproate-induced
Fanconi syndrome diagnosis. Furthermore, pyrexia
of unknown origin has been reported as the initial
presenting complaint in several cases of valproate-
induced Fanconi syndrome,6,8 prompting the inciden-
tal diagnosis of Fanconi syndrome. Accurate identi-
ﬁcation of valproate-induced Fanconi syndrome is
particularly pertinent since drug cessation has been
shown to resolve Fanconi syndrome and pyrexia of
unknown origin.6,8
Lessons learnt
When presented with complex phenotypes, Occam’s
razor often prevails; the simplest diagnosis with the
fewest assumptions is probably the correct one. For
this patient, the ﬁve key phenotypic characteristics
were:
1. Myoclonic epilepsy with weakness and hypotonia
2. Severe developmental disability
3. Fanconi syndrome
4. Pyrexia of unknown origin
5. Family history of Leigh syndrome
A mitochondrial disease was the preferred diag-
nosis that could explain the ﬁve features, and thus
prompted muscle biopsy analysis and genetic stu-
dies. Initially, there was suggestion that Fanconi
syndrome may have been secondary to valproate
therapy; however, in view of: (a) a probable
Figure 1. Pedigree of the proband. Individuals I2 and I3 report to be related; however, the degree of relatedness is unknown.
Individual I8 died at eight years from Leigh syndrome. II1 and II3 were miscarried at seven weeks. Affected individual shaded in
black. ‘þ’ denotes individual whose exome was sequenced. Dotted line denotes implied consanguinity based upon low level of
percentage heterozygosity present in the proband.
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mitochondrial disease; (b) the lag period before
valproate-induced Fanconi syndrome manifested
and (c) a pyrexia of unknown origin not at the
time known to be linked to valproate-induced
Fanconi syndrome, this was deemed unlikely and
whole exome sequencing analysis was performed
and targeted towards nuclear-encoded mitochondrial
genes. Although interrogation of mitochondrial can-
didate genes was unsuccessful, whole exome sequen-
cing facilitated a least-biased interrogation of the
patient’s entire exome enabling the identiﬁcation of
a causal mutation in KCTD7, which in turn enabled
us to:
1. Recognise KCTD7 as a cause of myoclonic
epilepsy with severe developmental delay and
myopathy
2. Exclude a mitochondrial disease
3. Reﬂect and reconsider the diagnosis of valproate-
induced Fanconi syndrome
4. Initiate a change in therapy
This highlights the importance of considering
drug reactions even if a patient has been on a drug
for some time. Furthermore, this has enabled us
to reﬂect on the provenance on his pyrexia at the
time of his admission; perhaps this was a manifest-
ation of valproate-induced Fanconi syndrome.
Although the discovery of the KCTD7 mutation is
unlikely to signiﬁcantly change the outcome for
our patient, giving his family a diagnosis can be
incredibly valuable for them. Although our initial
assumption of a mitochondrial disorder was incor-
rect, we applied available clinical information to
interpret exomic data and determine the causal muta-
tion responsible for the primary diagnosis of progres-
sive myoclonic epilepsy type 3. This subsequently
allowed us to re-evaluate our initial assumptions
and explain the outstanding phenotypic characteris-
tics not explained by the primary diagnosis.
Mutations of KCTD7 should be considered in chil-
dren who present with multifocal myoclonic seizures
with or without generalised tonic clonic seizures
Table 1. Rare homozygous variants.
Variant type Gene Exon Transcript ID Coding change Protein change PhyloP GERPþþ MAF
Non-synonymous_SNV ABLIM1 exon14 NM_001003408 C1387T R463W 0.99 5.42 .
Non-synonymous_SNV ADD3 exon14 NM_019903 G1780A V594I 0.99 5.54 .
Non-synonymous_SNV CPEB2 exon1 NM_001177383 C931G P311A . . .
Non-synonymous_SNV DMD exon1 NM_004014 G3A M1I . . .
Non-synonymous_SNV DUSP18 exon2 NM_152511 T167C V56A 0.99 4.92 .
Stopgain_SNV GPLD1 exon5 NM_001503 G418T G140X 0.99 5.03 .
Frameshift_deletion ICA1L exon6 NM_138468 544_545del 182_182del . . .
Non-synonymous_SNV KCTD7 exon3 NM_001167961 C322A L108M 0.92 2.77
Non-synonymous_SNV MDM1 exon14 NM_017440 G2105T R702L 0.99 5.11 .
Non-synonymous_SNV MED1 exon11 NM_004774 A819C L273F 0.97 2.71 .
Non-synonymous_SNV PARD3B exon20 NM_152526 G2910T E970D 0.97 2.06 .
Non-synonymous_SNV PKD1 exon19 NM_000296 C7502T A2501V 0.98 2.31 .
Non-synonymous_SNV SMARCA1 exon1 NM_139035 C92T P31L 0.99 3.1 .
Non-synonymous_SNV TBC1D10A exon7 NM_031937 A749C Q250P 0.99 4.12 .
Non-synonymous_SNV TDRD6 exon1 NM_001168359 G308T R103L 0.99 4.88 .
Note: Pan-exomic interrogation was targeted towards rare homozygous variants. Sixteen variants were prioritised on the following criteria: rejection
of synonymous variants; minor allele frequency <0.01; PhyloP score (a measure of conservation) >0.9; GERPþþ score positive; Logit score positive
(a pathogenic prediction measure) for non-synonymous variants; MaxEnt – Splicing variants scored above j2j. The row set in bold font identifies
pathogenic candidate variant.
MAF: minor allele frequency (1000 genomes project); SNV: single nucleotide variant; Variant type: nature of variant.
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associated with psychomotor regression after normal
development for the ﬁrst 10 months to 3 years.
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